KellyElizabethFaulkMD

PubMed

• Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study ...
  Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, Andrew J Carroll, Nyla A Heerema, Meenakshi Devidas, William L Carroll, Elizabeth A Raetz, Mignon L Loh, Stephen P Hung...> ;Pediatric Blood & Cancer. 2023 May 31
• 28 citations
  Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015
  Kelly Faulk, Amy Anderson-Mellies, Myles Cockburn, Adam L. Green> ;Plos One. 2020 Apr 23
• 9 citations
  Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin
  Kelly Faulk, Jenna Sopfe, Kristen Campbell, Deborah R. Liptzin, Arthur K. Liu, Anna Franklin, Carrye R. Cost> ;British Journal of Haematology. 2018 Oct 1
• 17 citations
  Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia
  Kelly Faulk, Lia Gore, Todd Cooper> ;Paediatric Drugs. 2014 Mar 18
• Join now to see all

Journal Articles

• Pulmonary Toxicity in Paediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin  
  Jenna M Sopfe, Kelly E Faulk, Arthur K Liu, Deborah R Liptzin, Carrye R Cost, British Journal of Haematology

Abstracts/Posters

• ATRT-30: Retrospective analysis of children with atypical teratoid rhabdoid tumor treated according to ACNS0333.
  Hoffman LM, Margol A, Faulk K, Hutchins S, Friedman G, Reddy A, Dhall G, Neuro Oncol

Lectures

• Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. 
  2019 ASCO Annual Meeting - 6/1/2019